Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study

Abstract

Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma.

Keywords

• survival
• multivariable analysis
• real-world cohort study